Fig. 5From: Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edemaMean plasma concentration of ASP8232 (pharmacokinetic analysis set). LDD, last dose dateBack to article page